… Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares LEIDEN, The Netherlands, … 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, the Netherlands … available on the SEC's website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands and … NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands … are available on the SEC’s website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today … Advisory Board. As Chief ADAR Scientist, he drives the development and optimization of the Company’s Axiomer … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
… pipeline program, QR-504a for Fuchs endothelial corneal dystrophy, is expected to advance to clinical testing in the … visual acuity, visual fields, and the objective measure of optical coherence tomography (OCT) retinal imaging, after a … The closing included the full exercise of underwriters’ option to purchase 2,076,923 additional shares. Gross …
… biomarker bile acids 72 hours after treatment. Further optimizations for EONs targeting NTCP have enabled … AX-0810 targeting NTCP for cholestatic diseases: clinical development candidate translational data to be reported, and … of deal to 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
… AX-0810 targeting NTCP for cholestatic diseases: clinical development candidate translational data to be reported, and … milestone income from existing partnership, and potential option to exercise for expansion of deal to 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
… biomarker study for QR-504a for Fuchs endothelial corneal dystrophy to be reported in 2022 Cash runway into mid-to-late … individuals from the Phase 1/2 Stellar trial in the Helia open-label extension study, which will include multiple dose … data from this trial in 2022. ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) …
… the existing proven delivery technology to the liver, the opportunity to monitor early biomarkers to establish target … in human genetics with a significantly lower chance of developing cardiovascular disease. ProQR intends to advance … 8 th annual Oligonucleotide and Precision Therapeutics (OPT) Congress and at the bi-annual RNA Editing Gordon …